Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

58.54 -0.89 (-1.50%)
Official Closing Price Updated: 7:00 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
88 89 Next >
News headline image
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Curious about the S&P500 stocks that are gapping on Tuesday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It ↗
The companies are facing off with their heart drugs in a growing disease area. 
Via Investor's Business Daily
News headline image
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
From Bristol Myers Squibb
Via Business Wire
News headline image
These Large-Cap Stocks With China And EU Exposure Got Crushed In The One Of The Most Volatile Trading Week (Apr 7-Apr 11): Are These In Your Portfolio? ↗
Large-cap stocks, such as PDD, PBR, KMX, APTV, STLA, CRWV, BMY, Z, BABA, and YUMC, saw significant declines due to trade tensions and missed earnings. 
Via Benzinga
Topics World Trade
News headline image
Why BRISTOL-MYERS SQUIBB CO (NYSE:BMY) qualifies as a good dividend investing stock. ↗
Analyzing BRISTOL-MYERS SQUIBB CO (NYSE:BMY)'s Dividend Potential. 
Via Chartmill
News headline image
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight ↗
Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells. 
Via Benzinga
News headline image
3 Value Stocks in the Doghouse
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
News headline image
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
Via Benzinga
Topics Government World Trade
News headline image
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash ↗
Here's why the 90-day tariffs delay doesn't help pharmaceutical companies. 
Via Investor's Business Daily
Topics Government Stocks World Trade
News headline image
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success ↗
Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program. 
Via Benzinga
News headline image
Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
What's going on in today's session: S&P500 movers ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday. 
Via Chartmill
News headline image
These S&P500 stocks are gapping in today's session ↗
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
News headline image
Tech Stocks Rebound As US Treasuries Tumble: What's Driving Markets Wednesday? ↗
Wall Street saw a tentative tech rebound early Wednesday, as investors begin to shrug off escalating U.S.-China trade tensions following a steep market selloff. 
Via Benzinga
Topics World Trade
News headline image
FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients ↗
The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase 3 CheckMate-8HW trial results. 
Via Benzinga
News headline image
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports ↗
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
News headline image
Bristol Myers Wins Dismissal Of Class Action Lawsuit Accusing It Of Fraudulently Acquiring Patents – Retail Sentiment Remains Subdued ↗
U.S. District Judge Edgardo Ramos in Manhattan said the plaintiffs failed to show that Bristol Myers and Celgene Corp violated the federal Sherman antitrust law. 
Via Stocktwits
Topics Fraud Government Intellectual Property
News headline image
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
From Bristol Myers Squibb
Via Business Wire
News headline image
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields ↗
 
Via Benzinga
News headline image
Is Pfizer Stock a Buy? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Laser-Focus on These Tariff-Proof Stocks Before It’s Too Late ↗
Stay calm amid tariff uncertainty with low-valued pharma and European stocks. Discover why these sectors offer protection and potential gains. 
Via InvestorPlace
Topics Government Intellectual Property World Trade
News headline image
Is Bristol Myers Squibb's High-Yielding Dividend Safe? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Exploring the top movers within the S&P500 index during today's session. ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday. 
Via Chartmill
News headline image
Is Bristol-Myers Squibb Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
Beat the S&P 500 With This Cash-Gushing Dividend Stock ↗
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
BMY: A High-Yielding Drug Stock With Great Growth Potential ↗
Bristol-Myers Squibb Co. traces its corporate beginnings back to 1887. Today, the company is a leader in developing innovative drugs like Eliquis for stroke prevention and Opdivo for cancer... 
Via Talk Markets
Topics Stocks / Equities
News headline image
Exploring the top movers within the S&P500 index during today's session. ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday. 
Via Chartmill
News headline image
5 Ways to Prepare for AI’s ‘Tower of Terror’ Moment ↗
As volatility rattles tech giants, investors are rotating into value stocks for stability and upside. Discover why this five-letter word could be the key to winning in 2025. 
Via InvestorPlace
Topics Artificial Intelligence Economy Government
News headline image
50-Year-Old Early Retiree Making $175,000 in Dividends Shares Portfolio - 'Now I Spend on Travel, Cars and Doing What I Want' ↗
 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
88 89 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.